<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of unscheduled bleeding in individuals using hormonal contraception</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of unscheduled bleeding in individuals using hormonal contraception</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of unscheduled bleeding in individuals using hormonal contraception</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison Edelman, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bliss Kaneshiro, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unscheduled uterine bleeding is a frequent side effect with many contraceptives and a common reason patients choose to discontinue their contraceptives. The frequency of unscheduled bleeding is highest in the first few months of use and then begins to diminish for most, but not all, methods. Interventions that prevent or treat unscheduled bleeding could improve contraceptive acceptability and increase compliance and thus lead to fewer unplanned pregnancies. </p><p>This topic will discuss the evaluation of patients with unscheduled bleeding, our approach to treatment, and the various treatment options. Related content on the selection of a contraceptive method is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p>In this topic, we will use the term "women" or "patient" to describe those who use female contraceptive methods. However, we recognize that not all people capable of pregnancy identify as women, and we encourage the reader to consider the specific counseling needs of transgender and gender nonbinary individuals. Clinicians should ask all patients who identify as male about their contraceptive needs as well.</p><p class="headingAnchor" id="H2"><span class="h1">DESCRIPTION OF BLEEDING PATTERNS</span><span class="headingEndMark"> — </span>The following terminology has been suggested in contraceptive trials to standardize the description of patients with bleeding related to contraceptive use [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Blood loss that requires the use of a tampon, pad, or panty liner.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spotting</strong> – Minimal blood loss that does not require use of any type of protection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episode of bleeding/spotting</strong> – Bleeding/spotting days bounded on either end by two days of no bleeding or spotting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scheduled bleeding or withdrawal bleeding</strong> – Any bleeding or spotting that occurs during contraceptive hormone-free intervals; bleeding may continue through days 1 to 4 of the subsequent active cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unscheduled bleeding and unscheduled spotting</strong> – Any bleeding that occurs while taking active contraceptive hormones, except bleeding that begins in the hormone-free interval and continues through days 1 to 4 of the subsequent active cycle.</p><p></p><p class="headingAnchor" id="H18877011"><span class="h1">MECHANISM</span><span class="headingEndMark"> — </span>The pathogenesis of unscheduled bleeding in patients using hormonal contraception is poorly understood [<a href="#rid2">2</a>]. Upon initiation of the method, unscheduled bleeding is thought to be due to a relatively thick endometrium transitioning to a relatively thin endometrium as a result of the dominant progestin component of all hormonal contraceptives [<a href="#rid3">3</a>]. With continuing use, it is thought to be the final step in a complex process activated by continuous exposure to exogenous sex steroids, particularly progestins [<a href="#rid4">4</a>]. In this environment, the endometrium develops a dense network of small, thin-walled, dilated, superficial veins and capillaries, which are fragile and prone to focal bleeding. The fragility of these vessels is due to alterations in their basement membranes and pericytes, as well as reduced structural support from the endometrial stroma and glands, which are also altered [<a href="#rid5">5,6</a>]. Altered matrix metalloproteinase activity appears to have a major role in this remodeling. Changes in endometrial perfusion, local vascular hemostasis, pro- and antioxidant processes, and migratory cells also appear to play a role [<a href="#rid7">7,8</a>]. </p><p class="headingAnchor" id="H1383831106"><span class="h1">CLINICAL SIGNIFICANCE</span><span class="headingEndMark"> — </span>While not medically dangerous, unscheduled bleeding is a common reason for discontinuation of the contraceptive method [<a href="#rid9">9-12</a>]. In a survey study of over 6700 United States women, 46 percent of women had stopped at least one contraceptive method because they were unsatisfied with it [<a href="#rid10">10</a>]. The main clinical significance is that the patient is then at risk for unintended pregnancy if another contraceptive method is not begun. In the United States, it is estimated that nearly one-half of all pregnancies are unintended [<a href="#rid13">13,14</a>]. The roles of education and reassurance are discussed in detail below. (See <a class="local">'Initial management'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Before assuming that unscheduled bleeding is result of hormonal contraception, the clinician must exclude identifiable pathology, as discussed below.</p><p class="headingAnchor" id="H2364161358"><span class="h2">Indications for additional evaluation</span><span class="headingEndMark"> — </span>Patients with severe pathology of the reproductive tract typically present with symptoms in addition to unscheduled bleeding. Common findings that accompany vaginal bleeding are cervicitis, cervical polyps, and uterine fibroids or polyps [<a href="#rid15">15-17</a>]. Patients who have pelvic inflammatory disease (PID; cervical motion tenderness OR uterine tenderness OR adnexal tenderness) in addition to cervicitis should be evaluated and treated appropriately. Women with erosive cervical lesions suggestive of cancer should be further evaluated with cervical biopsy and referral to a gynecologic oncologist, as needed. If a patient develops heavy or prolonged bleeding, or a significant change in bleeding pattern, and endometrial cancer is suspected, endometrial biopsy is indicated.</p><p>These diagnoses and evaluation of these entities are presented in detail in separate topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5460.html" rel="external">"Acute cervicitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2361308806"><span class="h2">Exclude pregnancy</span><span class="headingEndMark"> — </span>Even with the most effective contraceptive methods, pregnancy should be considered and excluded if a patient experiences a significant change in her bleeding pattern or if she develops pregnancy-type symptoms (breast tenderness, nausea, urinary frequency, fatigue). Pregnancy (intrauterine and ectopic) and hormonal contraceptives cause many of the same signs and symptoms. Absence of uterine bleeding and unscheduled bleeding are not only signs of early pregnancy but also common occurrences with hormonal methods of birth control, both combined and progestin-only. Pregnancy should always be excluded in patients with abrupt onset of amenorrhea, signs and symptoms of pregnancy, and inconsistent or incorrect contraceptive use.</p><p class="headingAnchor" id="H2525275810"><span class="h2">Questions to evaluate unscheduled bleeding</span><span class="headingEndMark"> — </span>In addition to a full medical history, the following questions can help guide further evaluation when a patient is experiencing unscheduled bleeding or spotting:</p><p class="bulletIndent1"><span class="glyph">●</span>What are the patient's main concerns? If bleeding is not bothersome, reassurance may be all that is needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What was her bleeding pattern prior to her current method of contraception? How has it changed?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>How many days does she bleed each month, how heavy is the bleeding, and how many bleeding episodes occur? These questions assess the magnitude of the problem and impact on the patient's quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the bleeding occur during or after sex or is it associated with pain or urinary symptoms? Bleeding associated with sex, pain, or urinary symptoms is unlikely to be related to contraception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What drugs or medications is she taking? Some drugs may affect bleeding patterns in contraceptive users [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has she been consistent in her use of contraception? Missing pills or taking them late affects hormone levels, which can cause unscheduled bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does she smoke? Smoking may affect bleeding patterns in contraceptive users [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has she had a new partner or is she at increased risk of a sexually transmitted infection? Cervicitis and PID can cause unscheduled bleeding. (See  <a class="medical medical_review" href="/d/html/5460.html" rel="external">"Acute cervicitis"</a> and  <a class="medical medical_review" href="/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When was her last cervical cancer screening? (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p></p><p>Beyond pregnancy testing, the decision to initiate a more detailed evaluation will depend on the answers to these questions and the type of contraceptive the patient is using. Unscheduled bleeding is common and expected with the use of progestin-only methods (contraceptive implants, progestin-only pills, depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, and the levonorgestrel-releasing intrauterine device [IUD]); further evaluation is not necessary unless indicated based on history (bleeding pattern was abnormal prior to contraceptive use), symptoms (menorrhagia, pain, vaginal discharge), or national cervical cancer screening guidelines, even if the unscheduled bleeding persists for the duration of contraceptive use. With the initiation of other contraceptive methods, including combined estrogen-progestin methods (pill, patch, ring) and the copper-releasing IUD, unscheduled bleeding is common and usually resolves over time; thus, further evaluation is not routinely necessary in the first six months of use.</p><p class="headingAnchor" id="H279851596"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A pelvic examination, both speculum and bimanual, is performed to exclude other reasons for unscheduled bleeding, including presence of cervical ectropion in users of combined estrogen-progestin contraceptives, infection (vaginitis, cervicitis, or PID), cervical malignancy, or trauma. Cervical cancer and sexually transmitted infection screening should be performed according to national screening guidelines. (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H1992979763"><span class="h2">Imaging and laboratory testing</span><span class="headingEndMark"> — </span>Depending on the findings and her symptoms, a pelvic ultrasound may be helpful to evaluate for possible uterine pathology (eg, fibroid, polyp). An endometrial biopsy is reasonable in patients over the age of 35 who had abnormal uterine bleeding for more than three months prior to starting contraception, patients with a history of endometrial hyperplasia, or patients with prolonged periods of unopposed estrogen stimulation secondary to chronic anovulation. Otherwise, the decision to biopsy the endometrium for patients who are experiencing unscheduled bleeding while using contraception will depend on the method they are using. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H3531674949"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>For patients in whom unscheduled bleeding is determined to be a result of their contraceptive, initial management includes counseling, a trial of observation if acceptable to the patient, and a trial of nonsteroidal anti-inflammatory drugs (NSAIDs) for those who prefer an intervention  (<a class="graphic graphic_algorithm graphicRef69054" href="/d/graphic/69054.html" rel="external">algorithm 1</a>). These suggestions are based mainly on our clinical experience, as the available data are limited. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of counseling</strong> – Dissatisfaction with unpredictable uterine bleeding is a common reason patients choose to discontinue hormonal contraception [<a href="#rid3">3,10</a>]. Prior to initiating contraception, patients should be thoroughly counseled about the range of bleeding patterns associated with various contraceptive options and informed that there is no evidence that unscheduled bleeding is associated with decreased contraceptive efficacy or other harmful effects. The frequency of unscheduled bleeding is highest in the first few months of use and then begins to diminish. Providing this information as a component of standard contraceptive counseling helps patients choose the method that best suits their needs. If warned of the frequency, course, and significance of unscheduled bleeding, they may be more willing to adhere to the method if bleeding irregularities occur. If they are reassured that the method is effective despite their bleeding, they will be less likely to abandon the method and risk unintended pregnancy.</p><p></p><p class="bulletIndent1">The unscheduled bleeding that occurs with contraceptive use is not associated with decreased contraceptive effectiveness unless bleeding is the result of nonadherence to the method (eg, missed pills). Users of short-acting hormonal methods, like oral contraceptive pills, the contraceptive patch, or the vaginal ring, should understand that missed or delayed ingestion, application, or placement can lead to unscheduled withdrawal bleeding. As an example, inconsistent pill use is associated with a 60 to 70 percent increase in the relative risk of unscheduled bleeding [<a href="#rid20">20</a>]. For these patients, we reinforce the importance of consistent use (reducing the number of missed doses, taking the pill at the same time each day) to improve the bleeding pattern [<a href="#rid17">17,20</a>]. Although supporting data are limited, computer or phone-based applications (apps) may provide helpful reminders for some patients [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Amenorrhea related to use of hormonal contraception does not require medical treatment. We reassure patients that amenorrhea is not a sign of reduced contraceptive efficacy nor is it dangerous to the patient. Patients who are at risk for pregnancy because of inconsistent contraceptive use should take a pregnancy test. (See <a class="local">'Exclude pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of observation</strong> – As discussed in the bullet above, the frequency of unscheduled bleeding is highest in the first few months of use. Thus, for patients who are otherwise low risk and comfortable with a trial of waiting, observation combined with consistent and correct use of the contraceptive method is a reasonable first step. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of NSAIDs</strong> – Despite reassurance, some patients desire an active intervention to reduce unscheduled bleeding. While supporting data for the use of NSAIDs in this clinical situation are limited, NSAIDs are generally well tolerated, low risk, easily available, and low cost. Therefore, in patients who tolerate NSAIDs and desire a treatment course, we prescribe <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 to 800 mg three times a day for 5 to 10 days. This drug is more readily available and less expensive than those studied (<a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> and <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a>). Data specific to NSAID use in patients with progestin-only implants are discussed below. (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential role of smoking cessation</strong> – Smokers are more likely than nonsmokers to experience unscheduled bleeding and spotting when taking estrogen-progestin contraceptive pills [<a href="#rid17">17,22</a>]. Bleeding is also more likely to persist through subsequent cycles [<a href="#rid17">17</a>]. Smoking cessation may result in improved cycle control and has other major health benefits [<a href="#rid3">3</a>]. We counsel all smokers about the options for smoking cessation. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1051649497"><span class="h1">TREATMENTS FOR CONTINUED BOTHERSOME BLEEDING</span></p><p class="headingAnchor" id="H507650594"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>For women who continue to have bothersome, persistent unscheduled bleeding, we again exclude gynecologic disease and pregnancy (see <a class="local">'Evaluation'</a> above). Once the contraceptive method is confirmed as the likely cause of unscheduled bleeding, we treat patients as summarized in the figure  (<a class="graphic graphic_algorithm graphicRef69054" href="/d/graphic/69054.html" rel="external">algorithm 1</a>). These suggestions are based mainly on our clinical experience, as data are limited. We are generally in agreement with the Centers for Disease Control and Prevention (CDC) United States Selected Practice Recommendations (US SPR) for Contraceptive Use, 2016  (<a class="graphic graphic_algorithm graphicRef89826" href="/d/graphic/89826.html" rel="external">algorithm 2</a>) [<a href="#rid23">23</a>]. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Fpdfs%2Frr6504.pdf&amp;token=mjmpv7xMHRIW2nr%2B3NCnsRRMR0IbKy23mk05qdX4YkRc8aJbpe1S4Ga2DOSAtgX5g3hShN2d9BpkHvGmgRRmdA%3D%3D&amp;TOPIC_ID=5474" target="_blank">US SPR</a> include information for providers regarding how contraceptive methods can be used and provide clinical guidance including information on the management and treatment of breakthrough bleeding.</p><p>As presented in the algorithm, our choice of treatment for unscheduled bleeding is based on the contraceptive method  (<a class="graphic graphic_table graphicRef121707" href="/d/graphic/121707.html" rel="external">table 1</a>). We start with therapies for which there is the best evidence and then move, as needed, to therapies with less evidence to support them. Whether the medical therapies discussed below result in a statistically significant reduction in symptoms is unclear because most trials have been small and/or had design flaws. </p><p class="headingAnchor" id="H15719109"><span class="h2">Estrogen-progestin contraceptives</span></p><p class="headingAnchor" id="H15719137"><span class="h3">Bleeding pattern</span><span class="headingEndMark"> — </span>Combined estrogen-progestin contraceptives include oral contraceptive pills (OCs), the transdermal contraceptive patch, and the vaginal contraceptive ring. An injectable combined estrogen-progestin contraceptive (Cyclofemina, Lunelle) is available in some countries.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen-progestin contraceptive pills</strong> – Unscheduled bleeding occurs in up to 50 percent of patients initiating cyclic OCs but decreases to less than 10 percent by the third month of use [<a href="#rid3">3,17</a>]. Randomized trials have reported that unscheduled bleeding is slightly higher with the lowest dose OCs (20 mcg ethinyl <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> [EE] component) than with 30 to 35 mcg EE pills [<a href="#rid24">24-26</a>]. There is no evidence that unscheduled bleeding is associated with decreased efficacy, even with the lowest dose products, as long as patients take their pills consistently (ie, no missed days and at the same time every day) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p></p><p class="bulletIndent1">Continuous use of OCs involves taking hormonally active pills daily and indefinitely without an induced withdrawal bleed. Extended use involves taking hormonally active pills daily for intervals of several months, thus minimizing scheduled bleeds to only a few times per year. Compared with the traditional monthly regimen, continuous and extended use of OCs decreases the overall number of scheduled bleeding days; however, they are associated with a high frequency of unscheduled bleeding and spotting, particularly during the first three months of use [<a href="#rid27">27-30</a>]. In trials, absence of all uterine bleeding and spotting during months 0 to 3 was achieved in less than 50 percent of continuous OC users, but this rate increased to 80 to 90 percent by months 10 to 12 [<a href="#rid27">27-29</a>]. The duration of unscheduled bleeding appears to be higher in patients using continuous OCs that contain <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) than in those that contain <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patch and ring</strong> – The frequency of unscheduled bleeding upon initiation of the contraceptive patch and ring is generally similar to that with OCs. Neither are approved for extended or continuous use, but a randomized trial comparing extended versus cyclic vaginal ring regimens reported that skipping the hormone-free interval increased unscheduled bleeding and reduced the amount of scheduled/withdrawal bleeding [<a href="#rid32">32</a>]. Further information on the use and bleeding patterns of the contraceptive vaginal ring and transdermal patch is presented elsewhere.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a>.)</p><p></p><p class="headingAnchor" id="H15719144"><span class="h3">Management</span><span class="headingEndMark"> — </span>Once the contraceptive method is confirmed as the likely cause, we take the approaches below based on the dosing regimen of the estrogen-progestin contraceptive.</p><p class="headingAnchor" id="H15719151"><span class="h4">Women using a cyclic regimen</span><span class="headingEndMark"> — </span>The optimal approach to treating women with persistent unscheduled bleeding from cyclic estrogen-progestin regimens is not known. For women who continue to have bothersome bleeding despite initial observation and/or a nonsteroidal anti-inflammatory drug (NSAID) trial, we proceed through the treatments in the order below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of vaginal contraceptive ring</strong> – For women who are having unscheduled bleeding with cyclic use of the combined estrogen-progestin pills and difficulty remembering to take a pill daily, another treatment option is to switch the patient to the estrogen-progestin vaginal ring (and stop the pill). Theoretically, this approach has two potential benefits: the patient is less likely to have unscheduled bleeding related to a "missed pill," and the vaginal ring is associated with more constant hormone levels than OCs. Although there are no studies evaluating this approach, the resulting elimination of wide swings in serum estrogen and progestin concentrations may reduce bothersome unscheduled bleeding. The ring has excellent cycle control under normal circumstances; however, this may not be the case in patients experiencing unscheduled bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of different oral contraceptive formulation or dose</strong> – For patients using estrogen-progestin pills, changing the formulation (ie, type of estrogen or progestin) or dose has been proposed. Although supporting data are limited, such a change is reasonable, particularly if the patient requests another OC product. Allowing her to switch is unlikely to worsen bleeding patterns and can improve overall satisfaction with OC use. Since most comparative studies report that women on OCs containing ≤20 mcg estrogen have more unscheduled bleeding, it makes sense to first switch to an OC with a higher estrogen dose (not to exceed 35 mcg of estrogen) [<a href="#rid26">26</a>]. There is less evidence for changing the progestin, but that is also an option  (<a class="graphic graphic_table graphicRef69223" href="/d/graphic/69223.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef87416" href="/d/graphic/87416.html" rel="external">table 3</a>) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">There is no evidence that monophasic OCs are associated with less unscheduled bleeding than phased OCs or that discontinuation due to dissatisfaction with bleeding patterns is different, but some studies have reported a lower incidence of unscheduled bleeding with triphasic rather than monophasic OCs [<a href="#rid34">34-37</a>]. There is also no evidence that pill products by different manufacturers, generic formulations, or different formulations of estrogen or progestin result in improved bleeding patterns [<a href="#rid17">17</a>]. Although uncontrolled studies have reported decreased bleeding after changing formulations, bleeding likely would have stopped with continued use of the initial OC regardless of the type of product used [<a href="#rid3">3</a>]. Patients who use a 21-day estrogen-progestin pill may have fewer unscheduled days of bleeding than patients using a 24-day regimen, although data are conflicting [<a href="#rid38">38,39</a>]. Of note, the total days of bleeding (scheduled plus unscheduled) will be higher for patients using a 21-day estrogen-progestin pill compared with 24-day regimen (mean 15.8 versus 13.2 days) [<a href="#rid38">38</a>]. Doubling or tripling the daily dose of OCs is not recommended to decrease unscheduled bleeding. While it may work for some patients, it has not been studied and may increase the risk of adverse events, such as thromboembolism. The authors do not provide supplemental estrogen-only as supporting data are lacking.</p><p></p><p class="headingAnchor" id="H15719158"><span class="h4">Women using continuous or extended regimens</span><span class="headingEndMark"> — </span>In most patients, unscheduled bleeding will decrease over time with continuous or extended use of the estrogen-progestin pill or vaginal ring. We do not advise continuous or extended use of the transdermal patch because of theoretical concerns for increased risk of thromboembolism. (See  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Risk of venous thrombotic events'</a> and  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Extended cycle use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormone-free trial</strong> – For patients who develop bothersome unscheduled bleeding with continuous or extended use of the combined estrogen-progestin pill or ring, we and other experts advise stopping the product for three to four consecutive days [<a href="#rid23">23,40</a>]. This hormone-free interval does not lessen contraceptive efficacy as long as it is done after the first 21 days of hormone use. </p><p></p><p class="bulletIndent1">We begin with a trial of a hormone-free interval because it is easy for a patient to stop and restart a product that she already has and there are limited trial data to support this approach [<a href="#rid41">41</a>]. The use of a three to four day hormone-free interval can be repeated whenever bothersome breakthrough bleeding occurs, as long as the patient has had at least 21 days of active pills before taking a hormone-free break. Over time, breakthrough bleeding episodes will become spaced out and stop. As an example, in one study where subjects were given the option of stopping the OC for four days if they had taken at least 24 days of active pills, the mean number of days of bleeding/spotting decreased from 19 days in the first 3 months of the study to 10 days in months 9 to 12 [<a href="#rid42">42</a>]. This technique should not be used more frequently than every three weeks in order to maintain contraceptive effectiveness. Data comparing a hormone-free interval with a change in product, discussed below, are not available. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Change in dose or formulation</strong> – For patients who continue to experience problematic unscheduled bleeding, we next offer a different OC because estrogen dose and progestin type appear to play a role in the amount of unscheduled bleeding patients experience when they start a continuous or extended method. In one trial, use of an OC pill containing 30 mcg of EE during the first year of use resulted in significantly less unscheduled bleeding than a pill containing 20 mcg of EE (35.5 versus 47.4 percent) [<a href="#rid43">43</a>]. In another trial, continuous use of OCs containing <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate resulted in significantly more bleeding-free days than use of pills containing LNG [<a href="#rid31">31</a>]. The LNG dose (90 versus 100 mcg) does not seem to make a difference [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H15719890"><span class="h2">Progestin-only contraceptives</span></p><p class="headingAnchor" id="H4"><span class="h3">Depot medroxyprogesterone acetate</span></p><p class="headingAnchor" id="H5"><span class="h4">Bleeding types</span><span class="headingEndMark"> — </span>Menstrual changes occur in most patients using depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA; subcutaneous or intramuscular formulations) [<a href="#rid3">3,45</a>]. Amenorrhea occurs in 12 percent of patients during the first three months of use, but by one year, 46 percent of users will be amenorrheic [<a href="#rid3">3,46</a>]. Although bleeding is rarely heavy, 25 percent of users will discontinue DMPA in the first year because of dissatisfaction with bleeding patterns [<a href="#rid47">47</a>]. Structured counseling prior to DMPA use increases continuation rates at one year of use and decreases discontinuation due to unscheduled bleeding. With continued use, the most common bleeding pattern is no bleeding; absence of all bleeding and spotting after one and five years of use is 50 and 80 percent, respectively [<a href="#rid48">48-50</a>]. Therefore, patients who are uncomfortable with cessation of uterine bleeding should be advised to use another method. (See  <a class="medical medical_review" href="/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p>The etiology of unscheduled bleeding in <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users is not clearly understood. Based on endometrial biopsy studies, atrophy and chronic endometritis appear to play a role [<a href="#rid3">3,51</a>]. Biopsy studies also suggest that the endometritis is related to atrophic endometrium rather than an infectious process [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H6"><span class="h4">Treatment options</span><span class="headingEndMark"> — </span>Since the frequency and duration of unscheduled bleeding decrease with continued administration of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>, many patients find it acceptable to wait for spontaneous resolution of the problem. For patients who want an intervention, medication may help with cessation of bleeding and spotting; however, there is no evidence to support routine use of this approach. For patients who desire therapy, we first offer an over-the-counter NSAID for five to seven days, as discussed above. (See <a class="local">'Initial management'</a> above.)</p><p>For patients who continue to experience bothersome bleeding, we offer the treatments presented in the order below: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental estrogen</strong> – For patients without contraindications to estrogen, we begin with a supplemental estrogen, either in a combined estrogen-progestin OC pill or as estrogen alone. Estrogen supplementation is thought to promote tissue repair and coagulation. The addition of estrogen alone does not affect the contraceptive efficacy of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> but does put the patient at risk for estrogen-related side effects [<a href="#rid3">3</a>]. Contraindications to estrogen therapy are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Candidates'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined estrogen-progestin pill</strong> – We prescribe a monophasic low-dose combined OC pill to treat unscheduled bleeding in <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users, which is consistent with the CDC's US SPR [<a href="#rid23">23</a>]. The patient is treated with 10 to 20 days of a combined estrogen-progestin OC pill containing 35 mcg of estrogen or less  (<a class="graphic graphic_table graphicRef69223" href="/d/graphic/69223.html" rel="external">table 2</a>). There are no data supporting one combined OC over another for this indication. Although combined OCs have not been well studied as a treatment for unscheduled bleeding with DMPA use, their effects on irregular bleeding are hypothesized to be similar to estrogen supplementation alone in DMPA users. The authors prefer a monophasic combined OC pill to estrogen-only therapy (below) because reproductive-aged patients are more familiar with this medication and it is relatively easy to obtain and inexpensive. </p><p></p><p class="bulletIndent2">Studies have not compared different progestin types or estrogen doses for the treatment of unscheduled bleeding with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use. When used alone (not in implant or DMPA users), studies suggest bleeding patterns are similar with 20 versus 30 mcg EE or 90 versus 100 mcg LNG combined OC pills, though bleeding may be less with a <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate pill than an LNG pill [<a href="#rid31">31,44</a>]. It is not known if these data apply to patients experiencing unscheduled bleeding with DMPA. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Estrogen only</strong> – Supplemental estrogen only (ie, not combined estrogen-progestin products) for prevention or treatment of active unscheduled bleeding in <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users appears to be helpful, but conflicting data exist. Trials have reported discordant findings, and some were flawed by high discontinuation rates by study participants [<a href="#rid53">53-57</a>]. If the patient has no contraindications to estrogen supplementation, 7 to 14 days of oral estrogen (1.25 mg conjugated estrogen or 2 mg of micronized <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>) or transdermal estrogen (a patch releasing 0.1 mg estradiol/24 hours) can be used.</p><p></p><p class="bulletIndent2">In the largest therapeutic trial of this approach, 278 <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users with unscheduled bleeding were assigned to receive either EE 50 mcg, <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> sulfate 2.5 mg, or placebo for 14 days [<a href="#rid55">55</a>]. Estrone worked no better than placebo while EE 50 mcg stopped bleeding, but it recurred after discontinuation of EE. However, 50 mcg EE pills are no longer advised for routine use because of increased risk for thromboembolic events. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">Mefenamic acid</a> – Mefenamic acid is an NSAID that is commonly used to treat pain and reduce dysmenorrhea. We suggest use of NSAIDs for five to seven days as an option for treatment of unscheduled spotting or light bleeding, although data supporting efficacy are limited. Mefenamic acid (500 mg twice per day for five days) was reported to be effective in control of bleeding during the first week of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use but was not statistically more effective than placebo by week 4 [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> – Tranexamic acid is an antifibrinolytic used during operative procedures in patients with hemophilia and for patients with heavy menstrual bleeding. A placebo-controlled trial of 100 <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users with unscheduled bleeding reported that tranexamic acid 250 mg orally four times per day for five days was effective in halting bleeding [<a href="#rid59">59</a>]. The tranexamic acid group had a significantly higher percentage of subjects in whom unscheduled bleeding stopped during the first week of treatment (88 versus 8.2 percent with placebo) and during the four-week follow-up period (68 versus 0 percent with placebo). The mean number of bleeding/spotting days was also significantly different between the groups (5.7 versus 17.5 days). The cost of tranexamic acid varies by region and may be prohibitive in some areas.</p><p></p><p class="headingAnchor" id="H143407718"><span class="h4">Treatments with limited data</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of unscheduled bleeding in new </strong><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a><strong> users</strong> – A few trials have studied use of supplemental estrogen for prevention of unscheduled bleeding in new DMPA users because unscheduled bleeding is especially common in this population and is the reason many patients do not return for a second injection. There is no high-quality evidence of efficacy, but some promising trends have been observed that require further study [<a href="#rid53">53,56,57</a>]. At this time, we do not advise prophylactic use of estrogen to prevent unscheduled bleeding in new DMPA users.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shortening the interval between </strong><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a><strong> injections</strong> – Increasing the frequency of DMPA injections is another approach to treatment of unscheduled bleeding. Although widely used, there are no studies evaluating the efficacy of this practice. We do <strong>not</strong> suggest shortening the interval between DMPA injections to treat unscheduled bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – Although a promising approach, more data are needed on use of mifepristone in patients with unscheduled bleeding from <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. In one trial of 20 patients starting DMPA, treatment with 50 mg mifepristone reduced unscheduled bleeding during the first three months of use compared with placebo (15 versus 36 percent) [<a href="#rid60">60</a>]. One limitation for United States clinicians is that a low-dose formulation of mifepristone (50 mg) is not available. The 200 mg dose used for termination of pregnancy has not been studied in the context of patients with unscheduled bleeding from contraception, is not available by prescription, and is costly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> – In a double-blind placebo-controlled randomized trial in 68 <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users with a current bleeding episode, doxycycline 100 mg twice daily for five days was not more effective than placebo for stopping a current episode of bleeding or for improving bleeding characteristics in the three months following treatment [<a href="#rid61">61</a>]. </p><p></p><p class="headingAnchor" id="H7"><span class="h3">Progestin-releasing implants</span><span class="headingEndMark"> — </span>Several progestin-releasing, long-acting contraceptive implants are available. A single rod, 68 mg etonogestrel-releasing system (Nexplanon) is available in many countries. Outside the United States, a two rod, 150 mg LNG-releasing system (Jadelle or Sino-implant) is available for use. Although the use of a six rod, 216 mg LNG-releasing system (Norplant) was stopped in the United States in 2002, patients may present with these implants. (See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p class="headingAnchor" id="H8"><span class="h4">Bleeding patterns</span><span class="headingEndMark"> — </span>All progestin contraceptive implants are associated with alterations in uterine bleeding patterns, which can range from amenorrhea to frequent, unscheduled bleeding [<a href="#rid54">54</a>]. Over a three-month period, 78 percent of <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> users reported some form of unscheduled bleeding [<a href="#rid62">62-64</a>]. Similarly, 75 to 80 percent of patients using the six rod LNG implant reported unpredictable bleeding patterns [<a href="#rid54">54,65</a>]. Amenorrhea may not be achieved or sustained with the progestin implants [<a href="#rid63">63</a>]. However, a favorable bleeding pattern within the first three months appears to predict a continued favorable pattern during the remainder of use, whereas those with unfavorable patterns have a 50 percent chance of improving [<a href="#rid63">63</a>].</p><p>One review reported that 6 to 23 percent of <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> users worldwide discontinued the method because of bleeding issues [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H9"><span class="h4">Management</span><span class="headingEndMark"> — </span>For patients with unscheduled bleeding related to progestin implants, our preference is expectant management rather than medical therapy. We begin with supportive counseling and reassurance that the bleeding is not dangerous and is likely to improve with time, typically in 6 to 12 months. However, some patients may find unscheduled bleeding bothersome enough to consider removal of the contraceptive implant. Before we remove a highly effective contraceptive, we offer patients medical therapy to minimize their symptoms.</p><p>There are no comparisons of the efficacy of the different treatment options for unscheduled bleeding, so the optimal treatment strategy is not known. Although the data are limited, we offer NSAIDs as initial therapy because they are inexpensive, well tolerated, and have few side effects. Unless contraindicated, we prescribe <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 to 800 mg three times a day for 5 to 10 days because this drug is more readily available and less expensive than those studied (<a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> and <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a>). If NSAID treatment does not improve the patient's symptoms, we the offer a trial of combined oral contraceptives (COCs), given in a cyclic fashion, for three to six months. The COCs can be used in conjunction with the NSAIDs for persistent bleeding. If none of these options resolve the bleeding, the patient may benefit from a different form of contraception. As discussed above, we exclude pregnancy prior to treating any symptoms. (See <a class="local">'Evaluation'</a> above.)</p><p>Studies evaluating the efficacy of different treatment options are discussed in the following sections.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">Mefenamic acid</a><strong> or </strong><a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> – Compared with placebo, studies in patients with etonogestrel implants report decreased bleeding with mefenamic acid 500 mg orally three times daily or celecoxib 200 mg orally daily, for a total treatment of five to seven days [<a href="#rid67">67,68</a>]. It is less clear if NSAIDs also reduce irregular bleeding resulting from the LNG implant. While the initial pilot studies supported NSAID use in these patients, subsequent larger studies did not confirm these findings [<a href="#rid54">54,69-71</a>]. NSAID use is consistent with the US SPR that suggest a trial of NSAIDs to treat unscheduled bleeding in patients with the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> (there are no recommendations for LNG implants, which are not available in the United States) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined estrogen-progestin oral contraceptive pills</strong> – Trials have reported decreased abnormal bleeding days in patients with LNG implants treated with COCs compared with placebo [<a href="#rid72">72,73</a>]. COCs can be used for 10 to 20 days in a trial to decrease bleeding [<a href="#rid23">23</a>]. Alternatively, patients may find it more convenient to cycle on COCs for one to three months to cause scheduled bleeding [<a href="#rid3">3</a>]. The authors typically treat the patient with one cycle of COCs and then reassess the symptoms. The number of days of scheduled bleeding may total more days than the unscheduled bleeding would have been, but patients tend to prefer scheduled to unscheduled bleeding. The authors prefer a monophasic COC pill to estrogen-only therapy (below) because reproductive-aged patients are more familiar with this medication and it is relatively easy to obtain and inexpensive. No one COC can be recommended over another for this indication, as studies have not compared different progestin types or estrogen doses for the treatment of unscheduled bleeding with etonogestrel implants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental estrogen</strong> <strong>only</strong> – Another option for reducing irregular bleeding associated with progestin implants is estrogen-only therapy, which stabilizes the endometrial lining. Exogenous estrogen can be administered as a pill or transdermal therapy.</p><p></p><p class="bulletIndent1">Most of the data on exogenous estrogen for treating unscheduled bleeding are from studies of the LNG implant. Trials of estrogen to treat unscheduled bleeding in patients with the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> have not been reported, but it is presumed that efficacy will be similar. The US SPR suggest a trial of combined estrogen-progestin oral contraceptives or estrogen-only therapy for patients with irregular bleeding resulting from the etonogestrel implant (there are no recommendations for LNG implants, which are not available in the United States) [<a href="#rid23">23</a>]. In general, we prescribe COC pills containing 35 mcg of estrogen or less, although the studies referenced in the US SPR used pills containing 50 mcg of estrogen. We do not use 50 mcg estrogen pills because of the increased risk of thromboembolic events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral conjugated estrogen 1.25 mg or </strong><a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a><strong> 2 mg</strong> – When administered once per day for seven days, these shorten episodes of unscheduled bleeding associated with the six rod LNG implant [<a href="#rid69">69,72,73</a>]. Use of these estrogens may also increase the interval between bleeding episodes [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transdermal estrogen (</strong><a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a><strong> 0.1 mg/day)</strong> – This estrogen form may improve unscheduled bleeding in patients with the LNG implant, but limited data do not suggest efficacy. In a trial of 64 patients with irregular bleeding treated with either transdermal estrogen or placebo, there was not a significant benefit to transdermal estrogen treatment [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selective estrogen receptor modulator</strong> <strong>(</strong><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a><strong> 10 mg bid for seven days) </strong>– Two double-blind trials have found that seven day course of tamoxifen for LNG implant (6 rod) users experiencing frequent or prolonged bleeding or spotting reported less unscheduled bleeding and more days of amenorrhea over three months [<a href="#rid75">75,76</a>]. Tamoxifen appears to inhibit endometrial angiogenesis (vessel formation), which may help to offset the abnormal vessel development mediated by progestin exposure that likely results in unscheduled bleeding. Tamoxifen can increase the risk of thromboembolic events and should not be used in those with additional risk factors for thromboembolic events.</p><p></p><p class="headingAnchor" id="H3233716496"><span class="h4">Other</span><span class="headingEndMark"> — </span>Other therapies that have been tried are ineffective, less well studied, or not widely available. The progesterone receptor modulators <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> and <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> appear to reduce unscheduled bleeding in small trials, but data are limited. A trial including 65 patients using etonogestrel implants comparing ulipristal with placebo reported five fewer days of bleeding in the patients receiving ulipristal [<a href="#rid77">77</a>]. Serum progesterone levels were nonovulatory in a subset of patients. Low doses of mifepristone (50 to 100 mg) also appear to be effective in reducing unscheduled bleeding in six rod LNG implant and <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> users [<a href="#rid78">78-81</a>]. Mifepristone, however, is not commercially available in these doses and theoretically may counteract the contraceptive efficacy of progestin implants.</p><p><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> and curcumin are ineffective [<a href="#rid70">70,82</a>]. Studies on progestin supplementation have been inconclusive [<a href="#rid69">69</a>]. <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a>, an antifibrinolytic, shows promise for six rod LNG implant users [<a href="#rid83">83</a>], and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> shows promise for <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> users [<a href="#rid84">84</a>], but results need to be confirmed with longer trials and longer periods of follow-up.</p><p class="headingAnchor" id="H13"><span class="h3">Progestin-only pills</span><span class="headingEndMark"> — </span>Progestin-only pills (POPs) are taken every day without interruption. They have an unpredictable effect on ovulation. Approximately 40 to 50 percent of patients who use POPs continue to have cyclic withdrawal bleeding, 40 percent will have irregular cycles or spotting, and 10 percent will have amenorrhea [<a href="#rid3">3</a>]. Having the patient take the POP at the same time every day and eliminating missed doses will minimize the frequency of unscheduled bleeding. (See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p>Many patients taking POPs do so because they cannot use or do not want estrogen therapy. For patients with bothersome unscheduled bleeding that does not improve with observation and/or NSAIDs, we next offer a trial of a different contraceptive method. For women who can tolerate estrogen, a trial of combined hormonal contraceptive is reasonable, although these women may prefer to just change methods rather than take both POPs and a combined hormonal contraceptive [<a href="#rid85">85</a>]. For women who are unable to take estrogen products, we advise a trial of observation, NSAIDs, and then a change in contraceptive method if unacceptable bleeding continues.</p><p>While low doses of <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> can decrease the number and duration of unscheduled bleeding episodes in POP users, especially in initial cycles, mifepristone is not readily available for this purpose [<a href="#rid86">86</a>]. (See <a class="local">'Treatments with limited data'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h2">Intrauterine devices</span><span class="headingEndMark"> — </span>Both copper and LNG-releasing intrauterine devices (IUDs) may cause changes in bleeding patterns, including heavier menses (primarily <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUDs</a>), intermenstrual spotting (both types), or amenorrhea (only <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a>). Amenorrhea does not require treatment. For patients who desire treatment of unscheduled bleeding, we offer NSAID treatment with <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 mg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 250 mg, or <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a> 500 mg three times per day for five to seven days. Small trials of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> in patients initiating the 52 mg LNG-releasing IUDs did not report reduced bleeding at three months compared with placebo [<a href="#rid87">87,88</a>]. A detailed discussion of evaluation and management of altered bleeding patterns with IUDs is presented separately. (See  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications"</a>.)</p><p class="headingAnchor" id="H18877109"><span class="h1">RETURN OF NORMAL MENSES AFTER DISCONTINUATION</span><span class="headingEndMark"> — </span>The patient's bleeding pattern should return to its pre-contraception pattern after discontinuation of the method. This can take as little as one cycle for estrogen-progestin contraceptives (pill, patch, ring) and most progestin-only methods (pill, implant, intrauterine device); however, it may take one year to 18 months in depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) users. Except for DMPA, the bleeding pattern usually returns to its pre-contraception baseline within three months.</p><p class="headingAnchor" id="H360646037"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8419.html" rel="external">"Patient education: Hormonal methods of birth control (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/8423.html" rel="external">"Patient education: Long-acting methods of birth control (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description and significance</strong> – Scheduled bleeding describes any uterine bleeding or spotting that occurs during contraceptive hormone-free intervals and may extend for one to four days into the next active cycle. Unscheduled bleeding is that which occurs outside the planned hormone-free time window. Prior to initiating any contraceptive method, counseling about the frequency, course, and significance of uterine bleeding helps avoid patient dissatisfaction and method discontinuation. Method discontinuation potentially places the patient at risk for unintended pregnancy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Description of bleeding patterns'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Clinical significance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation to exclude identifiable causes</strong> – Before the clinician can assume that unscheduled bleeding is a result of hormonal contraception, pregnancy and identifiable pathology must be excluded. Common findings that can present with unscheduled vaginal bleeding include cervicitis, cervical polyps, and uterine fibroids or polyps. (See <a class="local">'Evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – Initial management includes counseling and a period of observation, as bleeding will often resolve. Our general approach to management of unscheduled bleeding is summarized in the figure  (<a class="graphic graphic_algorithm graphicRef69054" href="/d/graphic/69054.html" rel="external">algorithm 1</a>). Patients are reassured that unscheduled bleeding that occurs with contraceptive use is not associated with decreased contraceptive effectiveness unless bleeding is the result of nonadherence to the method (eg, missed pills). For patients who desire an active intervention, we offer a trial of over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs). (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continued bothersome bleeding</strong> – For patients who continue to have bothersome unscheduled bleeding, we again exclude gynecologic disease and pregnancy. Once the contraceptive method is reconfirmed as the likely cause of unscheduled bleeding, we treat patients as summarized in the figure  (<a class="graphic graphic_algorithm graphicRef69054" href="/d/graphic/69054.html" rel="external">algorithm 1</a>). These suggestions are based mainly on our clinical experience, as the available data are of limited quality. We are generally in agreement with that of the Centers for Disease Control and Prevention (CDC) United States Selected Practice Recommendations for Contraceptive Use, 2016  (<a class="graphic graphic_algorithm graphicRef89826" href="/d/graphic/89826.html" rel="external">algorithm 2</a>). The approach is based on the specific contraceptive in use. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined estrogen-progestin contraception</strong> – Combined hormonal contraception includes oral pills, a transdermal patch, and vaginal contraceptive rings. Unscheduled bleeding occurs in up to 50 percent of patients initiating estrogen-progestin contraceptive pills but decreases to less than 10 percent by the third month of use. Taking the pills consistently and cessation of smoking may reduce unscheduled bleeding. (See <a class="local">'Estrogen-progestin contraceptives'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients using cyclic dosing of the estrogen-progestin pill, patch, or ring, the optimal approach to treating persistent unscheduled bleeding is not known. We offer patients a trial of NSAIDs, the vaginal contraceptive ring (for patients taking cyclic pills), and a method with a different dose or formulation, in that order. (See <a class="local">'Women using a cyclic regimen'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients using continuous or extended cycle regimens, most unscheduled bleeding will resolve over time. For patients who prefer an active intervention, limited data support a trial of a short hormone-free interval or changing to a different dose/formulation. Data comparing the two strategies are not available. We generally offer a trial of 3 to 4 hormone-free days, assuming the patient has already used the method for at least 21 days, because it is relatively easy to stop and restart a method that is already in use. (See <a class="local">'Women using continuous or extended regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Depot </strong><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a><strong> (DMPA)</strong> – We consider a period of observation for DMPA users with unscheduled bleeding, as the bleeding episodes will usually decrease over time. For those who desire an active intervention beyond NSAIDs, we offer a trial of supplemental estrogen, <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a>, and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a>, in that order. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progestin-only implants</strong> – Patients using progestin-releasing implants are counseled that irregular bleeding is a common side effect, is not dangerous, and frequently improves during the first year of use. For patients who desire treatment of unscheduled bleeding, we offer a trial of NSAID therapy and then supplemental estrogen. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progestin-only pills (POPs)</strong> – We counsel patients that POPs should be taken at the same time each day to minimize unscheduled bleeding. For patients with persistent bothersome bleeding, we suggest switching to another method, although estrogen supplementation may be reasonable for some patients. (See <a class="local">'Progestin-only pills'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intrauterine device (IUD)</strong> – For patients who desire treatment of unscheduled bleeding related to intrauterine contraception, we offer NSAID treatment with <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 mg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 250 mg, or <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a> 500 mg three times per day for five to seven days. (See <a class="local">'Intrauterine devices'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mishell DR Jr, Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007; 75:11.</a></li><li><a class="nounderline abstract_t">Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol 2017; 216:443.</a></li><li class="breakAll">Speroff L, Darney PD. A Clinical Guide For Contraception, 54th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011.</li><li><a class="nounderline abstract_t">Hickey M, d'Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 2002; 65:75.</a></li><li><a class="nounderline abstract_t">ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16:1527.</a></li><li><a class="nounderline abstract_t">Steroids and endometrial breakthrough bleeding. Proceedings of a meeting. Melbourne, Australia, 4-5 May 1999. Hum Reprod 2000; 15 Suppl 3:i.</a></li><li><a class="nounderline abstract_t">Guzeloglu Kayisli O, Kayisli UA, Basar M, et al. Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: Implications for Contraceptive- Associated Abnormal Uterine Bleeding. PLoS One 2015; 10:e0137855.</a></li><li><a class="nounderline abstract_t">Shapiro JP, Guzeloglu-Kayisli O, Kayisli UA, et al. Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. Contraception 2017; 95:592.</a></li><li><a class="nounderline abstract_t">Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception 1995; 51:155.</a></li><li><a class="nounderline abstract_t">Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.</a></li><li><a class="nounderline abstract_t">Grunloh DS, Casner T, Secura GM, et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122:1214.</a></li><li><a class="nounderline abstract_t">Diedrich JT, Zhao Q, Madden T, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol 2015; 213:662.e1.</a></li><li><a class="nounderline abstract_t">Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90.</a></li><li class="breakAll">Preventing unplanned pregnancy: Lessons from the states. Brookings Institute. June 2019 www.brookings.edu/research/preventing-unplanned-pregnancy-lessons-from-the-states/ (Accessed on June 26, 2019).</li><li><a class="nounderline abstract_t">Bontis J, Vavilis D, Panidis D, et al. Detection of Chlamydia trachomatis in asymptomatic women: relationship to history, contraception, and cervicitis. Adv Contracept 1994; 10:309.</a></li><li><a class="nounderline abstract_t">Krettek JE, Arkin SI, Chaisilwattana P, Monif GR. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol 1993; 81:728.</a></li><li><a class="nounderline abstract_t">Thorneycroft IH. Cycle control with oral contraceptives: A review of the literature. Am J Obstet Gynecol 1999; 180:280.</a></li><li><a class="nounderline abstract_t">Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16:263.</a></li><li><a class="nounderline abstract_t">Grossman MP, Nakajima ST. Menstrual cycle bleeding patterns in cigarette smokers. Contraception 2006; 73:562.</a></li><li><a class="nounderline abstract_t">Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 1996; 53:85.</a></li><li><a class="nounderline abstract_t">Smith C, Gold J, Ngo TD, et al. Mobile phone-based interventions for improving contraception use. Cochrane Database Syst Rev 2015; :CD011159.</a></li><li><a class="nounderline abstract_t">Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.</a></li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60:321.</a></li><li><a class="nounderline abstract_t">Akerlund M, Røde A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993; 100:832.</a></li><li><a class="nounderline abstract_t">Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus &gt;20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD003989.</a></li><li><a class="nounderline abstract_t">Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101:653.</a></li><li><a class="nounderline abstract_t">Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.</a></li><li><a class="nounderline abstract_t">Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439.</a></li><li><a class="nounderline abstract_t">Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93:420.</a></li><li><a class="nounderline abstract_t">Edelman AB, Koontz SL, Nichols MD, Jensen JT. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol 2006; 107:657.</a></li><li><a class="nounderline abstract_t">Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005; 106:473.</a></li><li><a class="nounderline abstract_t">Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011; :CD004861.</a></li><li><a class="nounderline abstract_t">Hampton RM, Fisher AC, Pagano S, LaGuardia KD. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. Fertil Steril 2009; 92:434.</a></li><li><a class="nounderline abstract_t">Poindexter AN, Burkman R, Fisher AC, LaGuardia KD. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med 2003; 48:163.</a></li><li><a class="nounderline abstract_t">Sulak P, Lippman J, Siu C, et al. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception 1999; 59:161.</a></li><li><a class="nounderline abstract_t">Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001; 63:289.</a></li><li><a class="nounderline abstract_t">Kaunitz AM, Burkman RT, Fisher AC, Laguardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol 2009; 114:1205.</a></li><li><a class="nounderline abstract_t">Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009; 80:445.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563.</a></li><li><a class="nounderline abstract_t">Godfrey EM, Whiteman MK, Curtis KM. Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review. Contraception 2013; 87:567.</a></li><li><a class="nounderline abstract_t">Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception 2012; 86:110.</a></li><li><a class="nounderline abstract_t">Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55:131.</a></li><li><a class="nounderline abstract_t">Kaneshiro B, Edelman A, Carlson NE, et al. Unscheduled bleeding with continuous oral contraceptive pills: a comparison of progestin dose. Contraception 2012; 86:22.</a></li><li><a class="nounderline abstract_t">Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.</a></li><li><a class="nounderline abstract_t">Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.</a></li><li><a class="nounderline abstract_t">Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687.</a></li><li><a class="nounderline abstract_t">Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181.</a></li><li><a class="nounderline abstract_t">Gardner JM, Mishell DR Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertil Steril 1970; 21:286.</a></li><li><a class="nounderline abstract_t">Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol 2008; 199:351.e1.</a></li><li><a class="nounderline abstract_t">Fraser IS. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 1983; 28:385.</a></li><li><a class="nounderline abstract_t">Thurman AR, Livengood CH, Soper DE. Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis. Contraception 2007; 76:49.</a></li><li><a class="nounderline abstract_t">Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Contraception 2010; 82:250.</a></li><li><a class="nounderline abstract_t">Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007; :CD003449.</a></li><li><a class="nounderline abstract_t">Said S, Sadek W, Rocca M, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod 1996; 11 Suppl 2:1.</a></li><li><a class="nounderline abstract_t">el-Habashy MA, Mishell DR Jr, Moyer DL. Effect of supplementary oral estrogen on long-acting injectable progestogen contraception. Obstet Gynecol 1970; 35:51.</a></li><li><a class="nounderline abstract_t">Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception 2002; 66:215.</a></li><li><a class="nounderline abstract_t">Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception 2004; 70:277.</a></li><li><a class="nounderline abstract_t">Senthong AJ, Taneepanichskul S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thai 2009; 92:461.</a></li><li><a class="nounderline abstract_t">Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003; 68:1115.</a></li><li><a class="nounderline abstract_t">Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN. Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial. Contraception 2012; 86:224.</a></li><li><a class="nounderline abstract_t">Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999; 60:1.</a></li><li><a class="nounderline abstract_t">Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:13.</a></li><li><a class="nounderline abstract_t">Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials. Fertil Steril 2009; 91:1646.</a></li><li><a class="nounderline abstract_t">Shoupe D, Mishell DR Jr, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant implant users. Obstet Gynecol 1991; 77:256.</a></li><li><a class="nounderline abstract_t">Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011; 83:426.</a></li><li><a class="nounderline abstract_t">Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai 2004; 87 Suppl 3:S64.</a></li><li><a class="nounderline abstract_t">Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use. J Med Assoc Thai 2009; 92:301.</a></li><li><a class="nounderline abstract_t">Díaz S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990; 42:97.</a></li><li><a class="nounderline abstract_t">d'Arcangues C, Piaggio G, Brache V, et al. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004; 70:451.</a></li><li><a class="nounderline abstract_t">Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 1999; 60:25.</a></li><li><a class="nounderline abstract_t">Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996; 174:919.</a></li><li><a class="nounderline abstract_t">Witjaksono J, Lau TM, Affandi B, Rogers PA. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod 1996; 11 Suppl 2:109.</a></li><li><a class="nounderline abstract_t">Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod 1996; 11 Suppl 2:115.</a></li><li><a class="nounderline abstract_t">Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception 2005; 72:432.</a></li><li><a class="nounderline abstract_t">Edelman AB, Kaneshiro B, Simmons KB, et al. Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial. Obstet Gynecol 2020; 136:323.</a></li><li><a class="nounderline abstract_t">Zigler RE, Madden T, Ashby C, et al. Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial. Obstet Gynecol 2018; 132:888.</a></li><li><a class="nounderline abstract_t">Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852.</a></li><li><a class="nounderline abstract_t">Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000; 15:1969.</a></li><li><a class="nounderline abstract_t">Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004; 70:47.</a></li><li><a class="nounderline abstract_t">Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2013; :CD003449.</a></li><li><a class="nounderline abstract_t">Edelman A, Boniface E, Schrote K, et al. Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized clinical trial of curcumin. Am J Obstet Gynecol 2023; 229:145.e1.</a></li><li><a class="nounderline abstract_t">Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception 2006; 73:253.</a></li><li><a class="nounderline abstract_t">Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295.</a></li><li><a class="nounderline abstract_t">Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill. Contraception 1982; 25:13.</a></li><li><a class="nounderline abstract_t">Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002; 17:2588.</a></li><li><a class="nounderline abstract_t">Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Hum Reprod 2018; 33:2002.</a></li><li><a class="nounderline abstract_t">Cohen MA, Simmons KB, Edelman AB, Jensen JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial. Contraception 2019; 100:391.</a></li></ol></div><div id="topicVersionRevision">Topic 5474 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161117" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988268" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unscheduled vaginal bleeding with progestin-only contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Unscheduled vaginal bleeding with progestin-only contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11861057" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vaginal bleeding disturbances and implantable contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425842" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ovarian and endometrial function during hormonal contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228650" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Steroids and endometrial breakthrough bleeding. Proceedings of a meeting. Melbourne, Australia, 4-5 May 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436918" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: Implications for Contraceptive- Associated Abnormal Uterine Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28433626" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621684" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900435" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contraceptive discontinuation attributed to method dissatisfaction in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259905" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Three-year continuation of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772190" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772190" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740997" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Detection of Chlamydia trachomatis in asymptomatic women: relationship to history, contraception, and cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469461" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cycle control with oral contraceptives: A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11945109" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interactions between antiepileptic drugs and hormonal contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16730484" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Menstrual cycle bleeding patterns in cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838484" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effect of desogestrel, gestodene, and other factors on spotting and bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115146" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mobile phone-based interventions for improving contraception use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623797" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Smoking and cycle control among oral contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715366" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218004" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846690" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 20 mcg versus&gt;20 mcg estrogen combined oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681866" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954519" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A multicenter, randomized study of an extended cycle oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157099" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056769" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of continuous versus cyclical oral contraception: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507938" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135576" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extended regimens of the contraceptive vaginal ring: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563141" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Types of progestogens in combined oral contraception: effectiveness and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18930189" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13677549" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10382078" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11672549" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935020" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19835718" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757653" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044386" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281416" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9115000" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22176792" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Unscheduled bleeding with continuous oral contraceptive pills: a comparison of progestin dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451329" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Contraceptive efficacy and safety of DMPA-SC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631785" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936897" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971505" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5508497" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18599013" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6230212" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586137" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705153" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443526" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8982739" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5409835" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of supplementary oral estrogen on long-acting injectable progestogen contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413614" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451330" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19374294" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668006" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325113" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10549446" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18330814" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effects of Implanon on menstrual bleeding patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18423453" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety and efficacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899135" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The significance of bleeding patterns in Norplant implant users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477684" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bleeding related to etonogestrel subdermal implant in a US population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21213495" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301720" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2117517" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical assessment of treatments for prolonged bleeding in users of Norplant implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541406" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10549449" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633669" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hormonal treatment for bleeding irregularities in Norplant implant users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8982752" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Oestrogen treatment for increased bleeding in Norplant users: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8982753" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307966" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tamoxifen treatment of bleeding irregularities associated with Norplant use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32649493" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130351" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369294" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966997" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208052" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828544" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37116825" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized clinical trial of curcumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16472565" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284061" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7060371" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351534" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295731" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31226322" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
